355P - Lower radiotherapy dose in patients with Hodgkin’s lymphoma- is it comparable to the past standard?
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
Surgery and/or Radiotherapy of Cancer
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586|
B.S. Yadav1, S.C. Sharma2, N. Kumar1, S. Ghoshal3
Hodgkin’s lymphoma patients survive longer so there is always of risk late term toxicity in these patients. The current trials are focussing to reduce number of chemotherapy cycles and radiation dose in these patients. Here we report our analysis of lower radiotherapy (RT) dose and compared it to the past standard in our setup.
From 2001 to June 2014, 170 patients with stage I to IV HL treated with combined modality or radiation alone were analyzed. Radiotherapy was given to 84(49%) patients; IFRT to 79(94%) and EFRT to 5(6%) patients respectively. We compared outcome of patients who received 30 Gy RT dose to those with 36Gy. Outcome compared were relapse rate, disease free survival (DFS) and overall survival (OS). DFS and OS were estimated using Kaplan-Meier method.
RT dose of 30 Gy was delivered to 36 patients and 36Gy to 48 patients. Mean age was 26 years(range 6-65 years). Median follow up was 44 months (range 9-210 months). Relapse was seen in 3(8.3%) patients with 30 Gy and were outside the RT field in all patients. In patients with 36Gy, relapse occurred in 6(12.5%) patients, with in RT field in 1 patient and outside in 5 patients respectively. DFS at 5 years was not statistically different with 30 Gy or 36Gy, 89% vs 84% respectively(p = 0.40). Similarly OS at 5 years was not statistically different with 30 Gy or 36Gy, 96% vs 92% respectively(p = 0.34).
In patients with Hodgkin’s lymphoma relapse rate DFS an OS were comparable RT dose of 30 Gy and 36 Gy. Future study will focus to further reduce the RT dose in these patients.
Clinical trial indentification
Legal entity responsible for the study
All authors have declared no conflicts of interest.